Clinical Trial Update: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) [Phase 2]

View source ↗

Summary

Phase 2 trial update on personalized immunotherapy-based regimens for recurrent gastric cancer is in early stages with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Gastric Adenocarcinoma
• Gastric Cancer
• Gastric Carcinoma

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Gastric Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 | Status: UNKNOWN